ABLYNX AND DOMANTIS SETTLE THEIR DISPUTE AND STOP THE ARBITRATION
PROCESS

(Thomson Reuters ONE) - GHENT, Belgium, 12 October, 2009 - Ablynx [Euronext Brussels: ABLX],today announced that it has reached a settlement with Domantis (partof the GlaxoSmithKline group of companies) concerning an allegeddispute relating to a settlement agreement which Ablynx and Domantisentered into in 2005.Under the new agreement Ablynx has received a license to the EuropeanWinter II patent which lay at the heart of the dispute and in returnwill pay Domantis low single-digit royalties on the first fiveNanobody® products which are commercialised.Dr Edwin Moses, CEO and Chairman of Ablynx, commented: "We are verypleased to have settled with Domantis so that we can focus on our keygoal of developing Nanobody® products and driving them through theclinic. We believe our investors want us, where possible, to put ourresources into R&D productivity rather than litigation. The fact thatthere are two Nanobodies® in Phase II trials, and by the end of 2009there will be a total of four in the clinic, is a testimony to thepower and promise of our technology."For more information, please contact:For international media enquiries: College Hill Life SciencesSue Charles, Justine Lamond,Dr John McIntyret: +44 (0)20 7866 7857e: ablynx(at)collegehill.comAblynx:Dr Edwin MosesChairman and CEOt: +32 (0)9 262 00 07m: +44 (0)7771 954 193 / +32 (0)473 39 50 68e: edwin.moses(at)ablynx.comEva-Lotta AllanChief Business Officert: +32 (0)9 262 00 75m: +32 (0)475 78 36 21 / +44 (0)7990 570 900e: eva-lotta.allan(at)ablynx.comhttp://hugin.info/137912/R/1347031/323743.pdfThis announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.

Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: hugin
Datum: 12.10.2009 - 18:00 Uhr
Sprache: Deutsch
News-ID 6817
Anzahl Zeichen: 0

contact information:
Town:

London

Kategorie:

Business News

Diese Pressemitteilung wurde bisher 318 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"ABLYNX AND DOMANTIS SETTLE THEIR DISPUTE AND STOP THE ARBITRATION
PROCESS"
steht unter der journalistisch-redaktionellen Verantwortung von

Ablynx (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).

Publication in Accordance With Article 14 of the Belgian Law of 2 May 2007 Regar ...

GHENT, BELGIUM -- (Marketwired) -- 08/27/13 -- (EURONEXT BRUSSELS: ABLX) today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to tr ...

Ablynx Announces Half-Year Results for 2013 ...

GHENT, BELGIUM -- (Marketwired) -- 08/21/13 -- (EURONEXT BRUSSELS: ABLX) today announced its results for the six-month period ending 30 June 2013, which have been prepared in accordance with the IAS 34 "Interim Financial Reporting" as adop ...

Ablynx Announces Warrant Exercise ...

GHENT, BELGIUM -- (Marketwired) -- 07/23/13 -- (EURONEXT BRUSSELS: ABLX) today announced, in conformity with Title II of the Law of 2 May 2007 and the Royal Decree of 14 February 2008, that an additional 273,913 common shares have been issued by the ...

Alle Meldungen von Ablynx